GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.

The Harvard motor neurone disease drug developer secured the return of Amgen Ventures for its series A round.

Dexcel Pharma formed part of a consortium that has supplied $80.5m in series A financing to Kriya Therapeutics, a gene therapy developer exploiting Stanford University research.

GV has invested in Ventus Therapeutics, an immunotherapy developer co-founded by faculty from multiple academic institutions.

UC Berkeley-aligned generalised robotics software developer Covariant, which emerged from stealth in January, has now assembled at least $67m of funding.

Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has collected capital from investors including TUS-Holdings.

NEA has led a series B1 round for the smart contact lens developer, whose existing shareholders include Stanford-StartX.

Federated Wireless secured the return of founding investor Allied Minds for a $13.7m extension that will expand wireless communications services forged on Virginia Tech research.

Repeatome drug developer Rome Therapeutics is based on intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.

SwanBio, based on research at Harvard Medical School, has secured a $20m extension to bring its series A round to $45m so far, with commitments to increase it to $77m.